ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Acronyms ESCORT-HU
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jan 2017 New trial record
- 06 Dec 2016 Results (n=1047) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.